NCT05439356 is a Phase 3 clinical trial of Colchicine in Ischemic Stroke, sponsored by Beijing Tiantan Hospital.

Who is sponsoring NCT05439356?

NCT05439356 is sponsored by Beijing Tiantan Hospital.

What drugs are being tested in NCT05439356?

Interventions in NCT05439356: Colchicine, Placebo colchicine.

What condition does NCT05439356 study?

NCT05439356 studies Ischemic Stroke, TIA.

Is NCT05439356 still recruiting?

NCT05439356 is currently completed. Last updated 25 June 2024.

Last reviewed 2024-06-25 · How we verify

NCT05439356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

Completed Phase 3 Last updated 25 June 2024

What this trial tests

Phase 3 trial testing Colchicine in Ischemic Stroke in 8,343 participants. Completed in 12 April 2024.

Timeline

11 August 2022

Primary endpoint
13 July 2023

12 April 2024

Quick facts

Lead sponsor	Beijing Tiantan Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	8,343
Start date	11 August 2022
Primary completion	13 July 2023
Estimated completion	12 April 2024
Sites	244 locations across China

Drugs / interventions tested

Colchicine (COLCHICINE) — full drug profile →
Placebo colchicine

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →
TIA — all drugs for TIA →

Sponsor

Beijing Tiantan Hospital

Who can join

40 and older, any sex, with Ischemic Stroke or TIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicentre, randomized, double-blind, placebo-controlled, investigator-sponsored study that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.
Li J, Meng X, Shi FD, Jing J, et al · · 2024 · cited 73× · PMID 38925803 · DOI 10.1136/bmj-2023-079061
Targeting inflammation to reduce recurrent stroke.
Zietz A, Gorey S, Kelly PJ, Katan M, et al · · 2024 · cited 46× · PMID 37800305 · DOI 10.1177/17474930231207777
Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial.
Wang Y, Li J, Johnston SC, Hankey GJ, et al · · 2023 · cited 17× · PMID 37060288 · DOI 10.1177/17474930231172312
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012
Ischemic stroke and intervention strategies based on the timeline of stroke progression: Review and prospects.
Xu A, Zhang H, Zhang Y, Wu J, et al · · 2025 · cited 5× · PMID 41049732 · DOI 10.1016/j.apsb.2025.07.026
[Colchicine-Phoenix from the ashes].
Lunzer R, Delle-Karth G, Zeitlinger M, Prager M, et al · · 2025 · cited 2× · PMID 39912853 · DOI 10.1007/s00508-024-02490-7
Association between High-Sensitivity C-Reactive Protein and Blood Pressure Variability in Subacute Stage of Ischemic Stroke.
Xu C, Fu Z, Wu W, Zhang J, et al · · 2023 · cited 2× · PMID 37508930 · DOI 10.3390/brainsci13070998
Inflammation-The new treatment target for ischaemic stroke prevention.
Gorey S, McCabe JJ, Kelly PJ. · · 2023 · PMID 41541100 · DOI 10.3389/fstro.2023.1241506

Verify or expand the search:

Other trials of Colchicine

Trials testing the same drug.

NCT07476625 — Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome · NA · not yet recruiting
NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05439356 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
Last refreshed: 25 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05439356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing